Single agent gemcitabine in the second-line treatment of advanced non-small cell lung cancer after treatment with taxane + platinum regimens

详细信息    查看全文

• 作者：Ugur Coskun (1) (2)
  Ali Osman Kaya (1)
  Süleyman Buyukberber (1)
  Mustafa Benekli (1)
  Aytug Uner (1)
  Mustafa Dikilitas (3)
  Banu Ozturk (1)
  Ramazan Yildiz (1)
  Secil Ozkan (1)
  Emel Yaman (1)
  Deniz Yamac (1)
  
• 关键词：Gemcitabine ; Non ; small cell lung cancer ; Second ; line
• 刊名：Medical Oncology
• 出版年：2008
• 出版时间：June 2008
• 年：2008
• 卷：25
• 期：2
• 页码：133-136
• 全文大小：147KB
• 参考文献：1. Cobo M, et al. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status. Lung Cancer 2007;56:255-2. can.2006.12.013">CrossRef
  2. Kosmas C, et al. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane?+?platinum-based regimens. Cancer Chemother Pharmacol 2007;59:51-. CrossRef
  3. Juergens R, Brahmer J, Ettinger D. Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter. Cancer Chemother Pharmacol 2007;59:621-. CrossRef
  4. unn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998;4:1087-100.
  5. Hanna N, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-7. CrossRef
  6. Shepherd FA, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
  7. Shepherd FA, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-2. CrossRef
  8. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2-2′–difluoro-2′–deoxycytidine). Cancer Res 1990;50:4417-2.
  9. Lund B, Kristjansen PEG, Hansen HH. Clinical and preclinical activity of 2-2′–difluoro-2′–difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 1993;19:45-5. CrossRef
  10. Cho KH, et al. A phase II study of single-agent gemcitabine as a second-line treatment in advanced non-small cell lung cancer. Jpn J Clin Oncol 2006;36:50-. CrossRef
  11. Crino L, et al. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 1999;7:2081-.
  12. Van Kooten M, et al. Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial. Br J Cancer 1999;81:846-. CrossRef
  13. Sculier JP, et al. A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer. The European Lung Cancer Working Party. Lung Cancer 2000;29:67-3. CrossRef
  14. Lara PN Jr, et al. Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial. Clin Lung Cancer 2004;6:102-.
  15. Gillenwater HH, Tynan M, Natoli S, et al. Second-line gemcitabine in refractory stage IV non small-cell lung cancer: a phase II trial. Clin Lung Cancer 2000;2:133-. CrossRef
  
• 作者单位：Ugur Coskun (1) (2)
  Ali Osman Kaya (1)
  Süleyman Buyukberber (1)
  Mustafa Benekli (1)
  Aytug Uner (1)
  Mustafa Dikilitas (3)
  Banu Ozturk (1)
  Ramazan Yildiz (1)
  Secil Ozkan (1)
  Emel Yaman (1)
  Deniz Yamac (1)
  
  1. Department of Medical Oncology, Gazi University Medical School, Ankara, Turkey
  2. 40. cadde 444.sokak, 5/5 Ebru Apt. ?ukurambar/100.Y?l, Ankara, Turkey
  3. Department of Medical Oncology, Erciyes University Medical School, Kayseri, Turkey
  

文摘

In this study, we investigated the activity of single agent gemcitabine in the second-line setting of non-small cell lung cancer (NSCLC). File records of 21 patients treated with single agent gemcitabine in advanced NSCLC who received one prior chemotherapy including a taxane and platinum combination were retrospectively evaluated. Treatment consisted of IV gemcitabine 1,250?mg/m2 on days 1 and 8, followed by a 1-week rest repeated every 3?weeks. A partial response was achieved in four (19%) patients. The median response duration was 16 (range, 12-2)?weeks. Six (29%) patients had a SD more than 3?months. The median time to progression was 16 (range, 8-2)?weeks. No complete response was observed. Median overall survival was 36?weeks for second-line gemcitabine in all patients (95%: CI 5-3?months). Hematological toxicity (all grades) was reported by 9 (42.9%) patients. One (4.75%) patient experienced grade 3/4 neutropenia. Grade 3/4 nausea and vomiting and mucositis were reported in one (4.75%) patient. In conclusion, this study shows that single agent gemcitabine is active and well tolerated as a second-line therapy for advanced NSCLC.